Trinity College Dublin

WASHINGTON, Aug. 12, 2025 /PRNewswire/ -- Tooth decay is the most common chronic disease of U.S. children and adults. Health and Human Services Secretary Robert F. Kennedy Jr. said he wants federal health agencies to be "dedicated to disease prevention and fighting chronic disease." Unfortunately, health officials are taking several misguided steps that could block access to fluoride, a mineral proven to prevent tooth decay. Continue Reading The mouth is the gateway to the human body, so poor oral health can impact overall health. Tooth decay is a transmissible disease that can result in sepsis, brain abscesses, lung infection and collapse, heart infection, and death. Fluoride is a mineral that exists naturally in lakes, rivers and groundwater, and it is proven at the recommended level to make tooth enamel more resistant to decay. Given that Kennedy has called for the end of water fluoridation, can the EPA conduct a review jointly with him that will truly be impartial? Post this Nearly 12 million U.S. residents have enough natural fluoride in their drinking water to prevent decay. Other communities adjust their fluoride level to the optimal level, which reduces decay by at least 25% for adults and children over their lifetimes. Considering these facts, it is deeply concerning that the Environmental Protection Agency (EPA) recently announced that it will conduct a scientific review of fluoride "in coordination with Secretary Kennedy and HHS." Given that Kennedy has called for the end of water fluoridation, can the EPA conduct a review jointly with him that will truly be impartial? It's a reasonable question to ask. The administration's attacks on fluoride and fluoridation are based on a misrepresentation of the evidence. For example, the Make America Healthy Again (MAHA) report raises safety concerns about fluoride by citing what it called "74 high-quality studies" that were reviewed by the National Toxicology Program (NTP). This is false. NTP reported that 70% of the studies "were rated as low quality (high risk of bias)." NTP's report found no link between lower IQ scores and the low concentrations of fluoride present in America's fluoridated tap water. The only link to IQs that the NTP reported — and with only "moderate confidence" — was to fluoride levels above 1.5 milligrams per liter. That level is more than double the level used for water fluoridation. Peer review is a vital process, separating robust scientific insights from weaker research. The MAHA report neglected to inform the public that NTP's report twice failed to clear the peer review process. After two rounds of peer review, the National Academies of Sciences wrote that NTP failed to provide "clear and convincing" evidence to back up its conclusions about fluoride. The National Academies also urged NTP to revise its report to clarify that its findings do not question the safety of water fluoridation in the United States. After receiving this negative review, the NTP abandoned its peer review relationship with the National Academies—one of the most respected scientific bodies in our country. Instead, NTP found a new set of peer reviewers. Many of NTP's studies used a flawed method to measure fluoride exposure during pregnancy. A recent research analysis concluded that spot urine samples are not a valid way to determine an individual's exposure. "An expectant mother typically urinates more than 1,400 times during pregnancy," said Dr. Johnny Johnson, President of the American Fluoridation Society. "To take only one to three urine samples out of 1,400 is not a reliable way to measure someone's fluoride exposure. When it comes to research, this approach is an example of garbage in, garbage out." The Food and Drug Administration (FDA) is another agency that appears to be headed toward a decision that could block access to fluoride. The FDA is proposing to ban fluoride supplements. In communities where the water lacks sufficient fluoride, parents are often prescribed fluoride supplements for their children. These supplements are designed to mimic the amount of fluoride that children would receive if they had access to fluoridated water. At an FDA hearing in July, opponents of fluoride cited the NTP report while ignoring or downplaying the report's serious flaws. During this hearing, opponents also claimed that topical exposure is the only way in which fluoride benefits teeth. This is false. A 2003 study showed that developing teeth benefit from exposure to fluoride even before they are visible in the mouth. The authors of this study wrote that without the ingestion of fluoride, "there was no significant prevention of [decay]." At the July hearing, an FDA official stressed that the decision on whether to ban fluoride supplements would be based on "data" and "science". If this is the case, it should carry tremendous weight that fluoride supplements are recommended by the U.S. Preventive Services Task Force. In its 2021 recommendation, the Task Force explained the importance of its recommendation, noting that tooth decay "in early childhood is associated with pain, loss of teeth, impaired growth, decreased weight gain, negative effects on quality of life, poor school performance, and future dental caries." Instead of relying on the Task Force's recommendations, the FDA official cited partial findings of the 2011 Cochrane review of fluoride supplements — stating that they found no benefit to primary (baby) teeth, while leaving out that they also found a 24% reduction in permanent teeth. The FDA's proposed ban on fluoride supplements is driven significantly by the FDA Commissioner's worry that because fluoride can inhibit plaque bacteria on teeth, it "may also kill intestinal bacteria important for a child's health." However, experts in this field have dismissed this concern. Microbiologists recently told Science News that they do not have concerns about fluoride's impact on the gut microbiome. Gary Moran, a microbiologist at Trinity College Dublin, said, "There is no convincing evidence to support a stance that fluoride use in childhood has a detrimental effect on microbiome development." Moran gave a presentation at the FDA's July hearing. Will the FDA base its decision about fluoride supplements on the science? Probably not. In fact, the FDA's announcement of this proposed ban included this made-up-my-mind quotation from Kennedy: "Ending the use of ingestible fluoride is long overdue." Researchers projected that if all U.S. states stopped water fluoridation, it would lead to 25 million additional decayed teeth over the next five years. One of Canada's largest cities learned a tough lesson after it stopped water fluoridation. Tooth decay in the city of Calgary increased significantly afterward. After fluoridation ended, the rate of children in Calgary whose teeth required urgent dental treatment under general anesthesia rose by 78%. This deterioration in health recently prompted Calgary to resume fluoridation. Behind every statistic is a story. Behind every number is a name. So much is at stake for people's health if Kennedy's opinions prevail over the evidence.Learn more about fluoride and fluoridation by visiting AmericanFluoridationSociety.org. Contact: Dr. Johnny Johnson at 727-409-1770 or [email protected] SOURCE American Fluoridation Society WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Appointments reflect ARTBIO's commitment to utilizing world-class experience and insights needed to advance alpha radioligand programs Company Co-founder Roy Larsen, Ph.D. will transition from Board of Directors to a new Technical Advisory Board within ARTBIO CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced four appointments to its Board of Directors: Maha Katabi, Ph.D., CFA is a General Partner at Sofinnova Investments. With more than two decades of experience in managing public and private biotech companies, Dr. Katabi will advise ARTBIO in their work to maximize investments for operations and growth strategies. Dr. Katabi received a Ph.D. in Pharmacology at McGill University and is a CFA Charterholder. Dr. Katabi was part of the early investment syndicate at RayzeBio, which was acquired by BMS in 2024. She currently serves on several public and private company boards. Robert Mittendorff, M.D., MBA is a General Partner and Head of Healthcare at B Capital Group, a global investment firm. His 20 years of experience as both a physician and public company executive will support ARTBIO's program expansion strategy. Dr. Mittendorff received his M.D. from Harvard University and MIT in the HST Program, and his MBA from Harvard Business School. Prior to B Capital Group, Dr. Mittendorff worked at Hansen Medical Inc., Merck, Boston Consulting Group, and at Kaiser Permanente. Julie O'Neill, MBA (Independent Director) is an experienced healthcare leader, having held senior manufacturing and operations roles at Alexion Pharmaceuticals and Gilead Sciences. She also chairs the board of Ireland's National Institute for Bioprocessing Research and Training. Mrs. O'Neill holds a Bachelor of Science in Pharmacy from Trinity College Dublin, an MBA from University College Dublin, and is a Chartered Director of The Institute of Directors in Ireland. Mrs. O'Neill serves on the boards of ICON plc, DBV Technologies, and Advancion Sciences (formerly Angus Chemical Company). Gabe Gelman has served as Head of Capital Solutions at Baker Bros. Advisors LP since 2025. Prior to joining Baker Brothers, Mr. Gelman had a 25-year career at Goldman Sachs where he most recently served as Head of Equity Capital Markets in the Americas. While at Goldman Sachs, Mr. Gelman advised on and led many high-profile biotechnology financings. Mr. Gelman holds a B.S.E. in Industrial Engineering from the University of Michigan. "Following our recent Series B funding round, these appointments will enable ARTBIO to rapidly advance multiple programs designed to have the highest patient impact," said Ted W. Love, M.D., Chairman of the Board at ARTBIO. "We're incredibly fortunate to have Maha, Robert, Julie and Gabe's perspectives informing the key stages of strategic growth at ARTBIO." Dr. Roy Larsen co-founded ARTBIO in 2021 and is a pioneer in the field of radiopharmaceuticals. With these latest board appointments, Dr. Larsen will transition into ARTBIO's newly created Technical Advisory Board. His dedication and ongoing partnership with ARTBIO are invaluable. "Dr. Larsen is a pillar of the radiopharma field – thousands of patients have benefited from his inventions already and his innovations will continue to have a positive impact on ARTBIO and the entire RLT industry for decades to come," said Emanuele Ostuni, CEO of ARTBIO. "I'm proud to call Roy a mentor and friend and look forward to our ongoing collaboration to bring novel cancer therapies to market." About ARTBIO ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 in metastatic castration resistant prostate cancer currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit , and follow us on LinkedIn. SOURCE ARTBIO WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TORONTO, June 26, 2025 /PRNewswire/ -- MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled "The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds", this review is the first to systematically compile data from 17 studies on fluorescence imaging.1 It conclusively establishes the crucial role of MolecuLight's technology in enhancing wound assessment by equipping clinicians with real-time, actionable information to effectively detect elevated bacterial burden, fundamentally transforming wound management. Continue Reading Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management MolecuLight Logo "This new publication is a crucial step forward for MolecuLight. It provides a comprehensive review of existing evidence, further underscoring the essential role of MolecuLight's fluorescence imaging in elevating wound care," said Anil Amlani, CEO of MolecuLight. "Bacterial bioburden leads to infections and is a critical factor inhibiting wound healing, and this paper clearly articulates how our technology empowers clinicians to not only identify the presence and location of bacteria but also to guide targeted interventions. Ultimately, this leads to faster and more effective healing for patients, further strengthening the growing body of evidence supporting our technology's profound impact." "As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds," said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT , experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. "The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care." This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,2 frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to: Enhance Assessment: Objectively determine the presence and location of bacteria in wounds that delays healing, increases infection risk, and can lead to devastating complications. Precisely Guide Treatment: Informs more precise hygiene and debridement, guides wound sampling for more informative results, and directs clinicians to the best wound treatment plan. In one publication included in the review2, MolecuLight led clinicians to change their treatment plans 68.9% of the time. Immediately Monitor Efficacy: Observe the real-time impact of interventions on bacterial load. MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs. About MolecuLight Inc. MolecuLight Inc. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. Photo - Photo - For sales, media or other inquiries or further information, please contact: MolecuLight Inc., Danielle Dunham, Director of Marketing and Product Management, T. +1.416.542.5524, [email protected], WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED